| Sign In to gain access to subscriptions and/or personal tools. |
The Faces Symbol Test, a newly developed screening instrument to assess cognitive decline related to multiple sclerosis: first results of the Berlin Multi-Centre FST Validation StudyKantstr. 125, D-10625 Berlin, Germany,schererpw@berlin. sireco. net
Department of Cognitive Psychology and Methodology, University of Basel, Basel, Switzerland
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Gross-Ziethener-Chaussee 16, 13355 Berlin/Bismarckstr. 70, 10627 Berlin
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Berlin MS Working Group, Berlin, Germany
Gross-Ziethener-Chaussee 16, 13355 Berlin/Bismarckstr. 70, 10627 Berlin
Berlin MS Working Group, Berlin, Germany
Berlin MS Society, Berlin, Germany
Berlin MS Society, Berlin, Germany
Emovis GmbH, Berlin, Germany
Emovis GmbH, Berlin, Germany
Schering Deutschland GmbH, Berlin, Germany
Schering AG, Berlin, Germany
Free University, Berlin, Germany
Technical University, Dresden, Germany Reliable, language-independent, short screening instruments to test for cognitive function in patients with multiple sclerosis (MS) remain rare, despite the high number of patients affected by cognitive decline. We developed a new, short screening instrument, the Faces Symbol Test (FST), and compared its diagnostic test characteristics with a composite of the Digit Symbol Substitution Test (DSST) and the Paced Auditory Serial Addition Test (PASAT), in 108 MS patients and 33 healthy controls. An Informant-Report Questionnaire, a Self-Report Questionnaire, and a neurologist's estimation of the Every Day Life Cognitive Status were also applied to the MS patients. The statistical analyses comprised of a receiver operating characteristic analysis for test accuracy and for confounding variables. The PASAT and DSST composite score estimated that 36.5% of the MS patients had cognitive impairment. The FST estimated that 40.7% of the MS patients were cognitively impaired (sensitivity 84%; specificity 85%). The FST, DSST and PASAT results were significantly correlated with the patients' physical impairment, as measured by the Expanded Disability Status Scale (EDSS). The results suggest that the FST might be a culture-free, sensitive, and practical short screening instrument for the detection of cognitive decline in patients with MS, including those in the early stages. Multiple Sclerosis 2007; 13: 402-411. http://msj.sagepub.com
Key Words: cognitive impairment Faces Symbol Test multiple sclerosis neuropsychology PASAT screening test
This version was published on April
1, 2007 Multiple Sclerosis, Vol. 13, No. 3,
402-411 (2007) This article has been cited by other articles:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
